What the FDA labels say about taking them together
Flumazenil and temazepam
Temazepam's FDA label of June 9, 2026 names flumazenil in its warnings section; flumazenil's label does not name temazepam itself but warns about its class (Benzodiazepines). The temazepam label: “Abrupt discontinuation or rapid dosage reduction of Restoril after continued use, or administration of flumazenil may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures).”
Check it at the source: the flumazenil FDA label on DailyMed (effective June 21, 2024, Hikma Pharmaceuticals USA Inc.); the temazepam FDA label on DailyMed (effective June 9, 2026).
What does the flumazenil label say about temazepam?
Flumazenil's label does not name temazepam itself; it warns about its class (Benzodiazepines):
Flumazenil label, contraindicationsCONTRAINDICATIONS Flumazenil is contraindicated: in patients with a known hypersensitivity to flumazenil or benzodiazepines. in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS ).
Flumazenil label, boxed warningTHESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE.
Source: FDA drug label (Flumazenil), Hikma Pharmaceuticals USA Inc., effective June 21, 2024 (SPL set 436f5616-9626-4b6a-9deb-2986444179d0), via openFDA; the full label on DailyMed
What does the temazepam label say about flumazenil?
Temazepam label, warningsAbrupt discontinuation or rapid dosage reduction of Restoril after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) ( see DRUG ABUSE AND DEPENDENCE, Dependence ).
Source: FDA drug label (RESTORIL), SpecGx LLC, effective June 9, 2026 (SPL set bc56f7fd-1aaf-48ff-8aa7-d467e59e1015), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Flumazenil | Temazepam | |
|---|---|---|
| Labeled for | n/a | Insomnia |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.18 per mL 0.5 mg/5 mL vial | $0.0767 per capsule 15 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once